Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 4/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829813 | 1.00 | KISS1R (0.37) | KISS1RCHRNB2CHRNA4CHRNB4ACACB | |
| SCHEMBL19742787 | 0.82 | CYP2D6 (0.34) | KISS1RCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1830903 | 0.78 | KISS1R (0.39) | KISS1RCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1835719 | 0.78 | ACACB (0.38) | KISS1RCHRNB2CHRNA4CHRNB4ACACB | |
| SCHEMBL26357789 | 0.78 | ALDH1A1 (0.37) | KISS1RCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL26047104 | 0.78 | ALDH1A1 (0.37) | KISS1RCHRNB2CHRNA4CHRNB4 | |
| SCHEMBL23914122 | 0.77 | — | — | |
| SCHEMBL1832757 | 0.75 | KISS1R (0.37) | KISS1RCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23157094 | 0.74 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRNB4ACACBCHRNA3 | |
| SCHEMBL14222481 | 0.74 | KISS1R (0.32) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | KISS1R 4172/4885CHRNB2 4675/4885CHRNA4 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.